Molecular determinants of resistance to antiandrogen therapy
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
Using microarray-based profiling of isogenic prostate cancer xenograft models, we found that a modest increase in androgen receptor mRNA was the only change consistently associated with the development of resistance to antiandrogen therapy. This increase in androgen receptor mRNA and protein was both necessary and sufficient to convert prostate cancer growth from a hormone-sensitive to a hormone-refractory stage, and was dependent on a functional ligand-binding domain. Androgen receptor antagonists showed agonistic activity in cells with increased androgen receptor levels; this antagonist-agonist conversion was associated with alterations in the recruitment of coactivators and corepressors to the promoters of androgen receptor target genes. Increased levels of androgen receptor confer resistance to antiandrogens by amplifying signal output from low levels of residual ligand, and by altering the normal response to antagonists. These findings provide insight toward the design of new antiandrogens.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“FKBP51 overexpression was not detected in a previous microarray analysis of the LAPC-4 xenografts (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“which is known to promote AI-type growth in human prostate cancer models (3)”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“AR overexpression is a signature of AI disease, and forcing AR expression in model systems is sufficient to generate AI growth and responsiveness to antiandrogens (3).”
From FKBP51 Promotes Assembly of the Hsp90 Chaperone Complex and Regulates Androgen Receptor Signaling in Prostate Cancer Cells (2010) · cites this paper as [3]
In the citing paper
“Several studies have provided evidence that this disease progression may be due in part to intratumoral synthesis of androgens, with castration-resistant prostate-cancer cells overexpressing the enzymes required for androgen biosynthesis.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [35]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261 · cited 1×
“Because xenograft-specific expression signatures are likely to obscure the gene expression changes responsible for the transition from hormone-sensitive to hormone-refractory state”
BackgroundShiau, A. K., Barstad, D., Loria, P. M., Cheng, L., Kushner, P. J., Agard, D. A., & Greene, G. L. (1998) · Cell · doi:10.1016/s0092-8674(00)81717-1 · Cited by 2,729 · cited 1×
“Because steroid receptor–antagonist complexes adopt a variety of conformation”
BackgroundThe development of androgen-independent prostate cancer.
Feldman, B. J., & Feldman, D. (2001) · Nature reviews. Cancer · doi:10.1038/35094009 · Cited by 2,326 · cited 1×
“The postulated mechanisms to explain resistance to hormone therapy can be separated into three general categorie”
BackgroundThe coregulator exchange in transcriptional functions of nuclear receptors
Glass, C. K., & Rosenfeld, M. G. (2000) · Genes & Development · doi:10.1101/gad.14.2.121 · Cited by 2,233
Self-citationActivation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964 · cited 1×
“The kinases and substrates responsible for androgen receptor activation in this setting are unknown, but it is presumed to occur through downstream phosphorylation of androgen receptor–associated proteins or through the androgen receptor itself, analogous to the estrogen recepto”
BackgroundLNCaP model of human prostatic carcinoma.
Horoszewicz, J. S., Leong, S. S., Kawinski, E., Karr, J. P., Rosenthal, H. E., Chu, T. M., MIRAND, E. A., & Murphy, G. P. (1983) · PubMed · Cited by 1,789
In vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Mutation of the Androgen-Receptor Gene in Metastatic Androgen-Independent Prostate Cancer
Taplin, M.-E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., Keer, H. N., & Balk, S. P. (1995) · New England Journal of Medicine · doi:10.1056/nejm199505253322101 · Cited by 1,253
Molecular Determinants for the Tissue Specificity of SERMs
Shang, Y., & Brown, M. (2002) · Science · doi:10.1126/science.1068537 · Cited by 1,146 · cited 1×
“Previous work has shown that the agonist-versus-antagonist response of nuclear receptors, such as the estrogen receptor, is altered by increased expression of coactivators (such as SRC-1) or by decreased expression of corepressors (such as NCoR”
BackgroundNongenotropic, Sex-Nonspecific Signaling through the Estrogen or Androgen Receptors
Kousteni, S., Bellido, T., Plotkin, L. I., O'Brien, C. A., Bodenner, D. L., Han, L., Han, K., DiGregorio, G. B., Katzenellenbogen, J. A., Katzenellenbogen, B. S., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00268-9 · Cited by 1,113
Cited by
Items 601–700 of 1,002
Donovan, M. J., Osman, I., Khan, F. M., Vengrenyuk, Y., Capodieci, P., Koscuiszka, M., Anand, A., Cordon‐Cardo, C., Costa, J. C., & Scher, H. I. (2009) · British Journal of Urology · doi:10.1111/j.1464-410x.2009.08747.x · Cited by 69
Wang, L. G., Johnson, E. M., Kinoshita, Y., Babb, J. S., Buckley, M. T., Liebes, L., Melamed, J., Liu, X., Kurek, R., Ossowski, L., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6017 · Cited by 73
“More recently, a microarray analysis of seven HR/hormone-sensitive isogenic pairs of human PC xenografts showed that among 12,500 gene probe sets tested, only AR mRNA was differentially expressed in all seven cases (10).”
BackgroundResultThelen, P., Scharf, J., Burfeind, P., Hemmerlein, B., Wuttke, W., Spengler, B., Christoffel, V., Ringert, R.-H., & Seidlová‐Wuttke, D. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi092 · Cited by 69
Chang, C.-Y., Abdo, J., Hartney, T., & McDonnell, D. P. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0072 · Cited by 70
Zhang, B., Lai, Y., Li, Y., Shu, N., Wang, Z., Wang, Y., Li, Y., & Chen, Z. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.12.053 · Cited by 69
“Although this is highly effective within 1–3 years for most patients, aggressive tumor eventually recurs with resistance to androgen deprivation therapy (Hellerstedt and Pienta, 2002), making so-called castration-resistant prostate cancer a major challenge in the field (Chen et al., 2004).”
BackgroundExpression, regulation and function of the ISGylation system in prostate cancer
Kießling, A., Hogrefe, C., Erb, S., Bobach, C., Fuessel, S., Wessjohann, L. A., & Seliger, B. (2009) · Oncogene · doi:10.1038/onc.2009.115 · Cited by 81
“Using cDNA micro arrays as tools for the determination of markers responsible for resistance to anti-androgen therapy, an increased AR expression was identified as a unique factor consistently associated with the development of a hormone-refractory disease (Chen et al., 2004).”
BackgroundMethodInfluentialHeterogeneous Nuclear Ribonucleoprotein K Is a Novel Regulator of Androgen Receptor Translation
Mukhopadhyay, N. K., Kim, J., Cinar, B., Ramachandran, A., Hager, M. H., Vizio, D. D., Adam, R. M., Rubin, M. A., Raychaudhuri, P., Benedetti, A. D., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2308 · Cited by 69
Combinatorial androgen receptor targeted therapy for prostate cancer
Singh, P., Uzgare, A. R., Litvinov, I. V., Denmeade, S. R., & Isaacs, J. T. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00797 · Cited by 68
“This results in a two- to three-fold increase in the levels of AR protein with androgen ablationresistant prostatic cancer cells (Chen et al. 2004).”
BackgroundInfluentialDai, B., Chen, H., Guo, S., Yang, X., Linn, D. E., Sun, F., Li, W., Guo, Z., Xu, K., Kim, O., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4610 · Cited by 77
“Increased AR expression was shown to be associated with the development of anti-androgen therapy resistance (5).”
BackgroundRecent developments in antiandrogens and selective androgen receptor modulators
Haendler, B., & Cleve, A. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.002 · Cited by 80
Regulation of androgen receptor splice variant AR3 by PCGEM1
Zhang, Z., Zhou, N., Huang, J., Ho, T.-T., Zhu, Z., Qiu, Z., Zhou, X., Bai, C., Wu, F., Xu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7139 · Cited by 70
“Although initial response of prostate cancer to ADT is effective, these patients inevitably develop the resistance, i.e., castration- resistant prostate cancer (CRPC) [1, 2].”
Liu, P., Li, S., Gan, L., Kao, T. P., & Huang, H. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-2038 · Cited by 67
“The AR is required for the growth of ADI-PCa cells (12, 13 ).”
BackgroundInfluentialLigand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer.
Lyons, L. S., Rao, S., Balkan, W., Faysal, J., Maiorino, C. A., & Burnstein, K. L. (2008) · Molecular Endocrinology · doi:10.1210/me.2007-0158 · Cited by 67
Biology of Cancer-Testis Antigens and Their Therapeutic Implications in Cancer
Nin, D. S., & Deng, L. (2023) · Cells · doi:10.3390/cells12060926 · Cited by 80
Selectively Targeting Prostate Cancer with Antiandrogen Equipped Histone Deacetylase Inhibitors
Gryder, B. E., Akbashev, M. J., Rood, M. K., Raftery, E. D., Meyers, W. M., Dillard, P., Khan, S. A., & Oyelere, A. K. (2013) · ACS Chemical Biology · doi:10.1021/cb400542w · Cited by 73
Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications
Terada, N., Akamatsu, S., Kobayashi, T., Inoue, T., Ogawa, O., & Antonarakis, E. S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017719215 · Cited by 74
Genomic analysis of DNA repair genes and androgen signaling in prostate cancer
Jividen, K., Kedzierska, K., Yang, C., Szlachta, K. A., Ratan, A., & Paschal, B. M. (2018) · BMC Cancer · doi:10.1186/s12885-018-4848-x · Cited by 71
“We used publicly-available gene expression microarray data from seven prostate cancer xenografts (CWR22, LAPC4, LAPC9, LNCaP, LuCaP23, LuCaP35, and LuCaP41) for which there are hormone sensitive (HS) and hormone resistant (HR) isogenic lines [20].”
MethodInfluentialLotan, T. L., Tomlins, S. A., Bismar, T. A., van der Kwast, T., Grignon, D. J., Egevad, L., Kristiansen, G., Pritchard, C. C., Rubin, M. A., & Bubendorf, L. (2020) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001450 · Cited by 76
Jia, L., Shen, H. C., Wantroba, M., Khalid, O., Liang, G., Wang, Q., Gentzschein, E., Pinski, J. K., Stanczyk, F. Z., Jones, P. A., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00581-06 · Cited by 66
“sufficient to convert androgen-sensitive PCa to an androgenindependent state (5).”
BackgroundSun, F., Indran, I. R., Zhang, Z. W., Tan, M. H. E., Li, Y., Lim, Z. L. R., Hua, R., Yang, C., Soon, F.-F., Li, J., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv040 · Cited by 66
“Mechanisms critical in the progression of CRPC include intratumoral androgen synthesis (4), AR overexpression and mutations that sensitizes AR to low androgen concentrations or alternative ligands (5,6), changes in the levels of AR transcriptional cofactors (7) and expression of constitutively active AR COOH-terminal…”
BackgroundOct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer
Obinata, D., Takayama, K., Urano, T., Murata, T., Kumagai, J., Fujimura, T., Ikeda, K., Horie‐Inoue, K., Homma, Y., Ouchi, Y., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26043 · Cited by 67
Expression of cancer/testis antigens in prostate cancer is associated with disease progression
Suyama, T., Shiraishi, T., Zeng, Y., Yu, W., Parekh, N., Vessella, R. L., Luo, J., Getzenberg, R. H., & Kulkarni, P. (2010) · The Prostate · doi:10.1002/pros.21214 · Cited by 66
“Unfortunately, at present, there is no known cure for metastatic PCa and standard treatments such as androgen deprivation and chemotherapy that may provide transient relief are not considered curative [2,3].”
BackgroundSelf-citationRokhlin, O. W., Glover, R. B., Guseva, N. V., Taghiyev, A. F., Kohlgraf, K. G., & Cohen, M. B. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0085 · Cited by 66
“There is strong evidence that down-regulation of AR expression should be considered as the main strategy for the treatment of advanced prostate cancer (12, 31).”
BackgroundWhat goes on behind closed doors: physiological versus pharmacological steroid hormone actions
Simons, S. S. (2008) · BioEssays · doi:10.1002/bies.20792 · Cited by 67
“Androgen resistance correlates with increased AR levels in prostate tumor xenograph models (108), as expected from tissue culture studies where increases in AR decrease the EC50 for gene induction and increased the percent partial agonist activity of antiandrogens.”
BackgroundGenetic alterations and changes in expression of histone demethylases in prostate cancer
Suikki, H. E., Kujala, P. M., Tammela, T. L. J., van Weerden, W. M., Vessella, R. L., & Visakorpi, T. (2010) · The Prostate · doi:10.1002/pros.21123 · Cited by 72
“Experimental studies have shown that overexpression of AR can transform androgen-dependent PC xenografts to androgen-independent ones [7].”
Self-citationWang, L., Wang, J., Xiong, H., Wu, F., Lan, T., Zhang, Y., Guo, X., Wang, H., Saleem, M., Jiang, C., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.022 · Cited by 67
“The discovery that persistent androgen receptor (AR) signaling plays a crucial role in the progression of CRPC leads to “second generation” ADT modalities (Chen et al., 2004; Tran et al., 2009), such as the Food and Drug Administration-approved androgen synthesis blocker abiraterone (2011, FDA) and the second generati…”
Lee, W.-J., Chien, M., Chow, J., Chang, J.-L., Wen, Y., Lin, Y.-W., Cheng, C., Lai, G., Hsiao, M., & Lee, L.-M. (2015) · Scientific Reports · doi:10.1038/srep10420 · Cited by 66
“Although most patients initially respond to androgen deprivation therapy, they ultimately progress to a castration-resistant prostate cancer that acquires the ability to evade cell death under androgen-depleted conditions 3,4 .”
Locke, J. A., Guns, E. S. T., Lehman, M., Ettinger, S., Zoubeidi, A., Lubik, A. A., Margiotti, K., Fazli, L., Adomat, H. H., Wasan, K. M., et al. (2009) · The Prostate · doi:10.1002/pros.21057 · Cited by 73
Cancer stem cell in prostate cancer progression, metastasis and therapy resistance
Verma, P., Shukla, N., Kumari, S., Ansari, M. S., Gautam, N. K., & Patel, G. K. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188887 · Cited by 70
Kawata, H., Ishikura, N., Watanabe, M., Nishimoto-Kakiuchi, A., Tsunenari, T., & Aoki, Y. (2010) · The Prostate · doi:10.1002/pros.21107 · Cited by 67
“[30] reported that LNCaP and LAPC-4 cells overexpressing AR proliferated from low levels of androgen, causing high tumor incidence in castrated mice and resistance to bicalutamide.”
Miyamoto, H., Altuwaijri, S., Cai, Y., Messing, E. M., & Chang, C. (2005) · Molecular Carcinogenesis · doi:10.1002/mc.20121 · Cited by 70
“cells was necessary and sufficient for progression to the androgen-independent phenotype [19].”
BackgroundThe role of epithelial plasticity in prostate cancer dissemination and treatment resistance
Bitting, R. L., Schaeffer, D., Somarelli, J. A., García-Blanco, M. A., & Armstrong, A. J. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9483-z · Cited by 71
“Androgen deprivation therapy (ADT) through either chemical or surgical castration is the first-line therapy for metastatic disease; however, response is temporary, and patients consistently progress to castration-resistant prostate cancer (CRPC), although at variable rates [2, 3].”
BackgroundShiota, M., Takeuchi, A., Song, Y., Yokomizo, A., Kashiwagi, E., Uchiumi, T., Kuroiwa, K., Tatsugami, K., Fujimoto, N., Oda, Y., et al. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0017 · Cited by 69
“…at 12/13/2018 12:24:32PM via free access mechanisms of AR overexpression in CRPC appears to be a promising strategy for developing novel therapeutics for CRPC, especially since AR downregulation suppresses tumor growth even in CRPC (Zegarra-Moro et al. 2002, Chen et al. 2004, Scher & Sawyers 2005).”
Rajaram, P. S., Rivera, A., Muthima, K., Olveda, N., Muchalski, H., & Chen, Q. (2020) · Molecules · doi:10.3390/molecules25102448 · Cited by 68
“The clearer understanding of the structure and function of the androgen receptor revealed that the androgen receptor plays a pivotal role for not only CSPC but also CRPC [13].”
BackgroundINTEGRATIVE BIOLOGY OF PROSTATE CANCER PROGRESSION
Tomlins, S. A., Rubin, M. A., & Chinnaiyan, A. M. (2006) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100047 · Cited by 66
mTOR Inhibitors in Castration-Resistant Prostate Cancer: A Systematic Review
Statz, C. M., Patterson, S. E., & Mockus, S. M. (2016) · Targeted Oncology · doi:10.1007/s11523-016-0453-6 · Cited by 71
A Pyrrole-Imidazole Polyamide Is Active against Enzalutamide-Resistant Prostate Cancer
Kurmis, A. A., Yang, F., Welch, T. R., Nickols, N. G., & Dervan, P. B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2503 · Cited by 65
“The LNCaP/AR cell line overexpresses full length AR, modeling castration resistance (14).”
BackgroundSchlinger, B. A., Barske, J., Day, L. B., Fusani, L., & Fuxjager, M. J. (2013) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2013.04.001 · Cited by 70
“This led us to conclude that flutamide (i) began to function as an AR agonist after 2 weeks of treatment (Shet et al., 1997; Wirth and Froschermaier, 1997), (ii) up-regulated AR or other downstream signaling mechanisms (Chen et al., 2004), (iii) or both.”
BackgroundJackson, T. L. (2004) · Neoplasia · doi:10.1593/neo.04259 · Cited by 64
“[12] recently found that an increase in androgen receptor mRNA was the only change that could be consistently associated with the development of hormone resistance across seven human prostate cancer xenografts (LuCaP and LNCap included).”
BackgroundMethodInfluentialPatki, M., Chari, V., Sivakumaran, S., Gonit, M., Trumbly, R. J., & Ratnam, M. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.438473 · Cited by 76
Zhang, Y., Won, S., Jiang, C., Lee, H., Jeong, S., Lee, E., Zhang, J., Ye, M., Kim, S., & Lü, J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0670-3 · Cited by 68
Linn, D. E., Yang, X., Xie, Y., Alfano, A., Deshmukh, D., Wang, X., Shimelis, H., Chen, H., Li, W., Xu, K., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.338350 · Cited by 73
Discovery of prostate cancer biomarkers by microarray gene expression profiling
Sørensen, K. D., & Orntoft, T. F. (2009) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.09.74 · Cited by 65
Bruno, R. D., Gover, T. D., Burger, A. M., Brodie, A. M. H., & Njar, V. C. O. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0336 · Cited by 67
“androgens and AR antagonists have been shown to act as partial agonists in prostate cancer cells expressing mutated and/or overexpressed AR (3, 4).”
Epigenetics in Prostate Cancer
Albany, C., Alva, A. S., Aparicio, A. M., Singal, R., Yellapragada, S. V., Sonpavde, G., & Hahn, N. M. (2011) · Prostate Cancer · doi:10.1155/2011/580318 · Cited by 79
“The AR is a nuclear hormone receptor, which is activated by binding of androgen ligands.”
BackgroundPaller, C. J., Pu, H., Begemann, D. E., Wade, C. A., Hensley, P. J., & Kyprianou, N. (2018) · The Prostate · doi:10.1002/pros.23708 · Cited by 69
“of therapeutic response in patients with mCRPC and persistent AR signaling and AR splice variants are validated therapeutic targets in CRPC.(14,15) Phenotypically the process of epithelial-mesenchymal”
BackgroundInfluentialMartin, S. K., Banuelos, C. A., Sadar, M. D., & Kyprianou, N. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.10.014 · Cited by 67
Endo, S., Oguri, H., Segawa, J., Kawai, M., Hu, D., Xia, S., Okada, T., Irie, K., Fujii, S., Gouda, H., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00939 · Cited by 67
Zhang, Y., Ming, A., Wang, J., Chen, W., & Fang, Z. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107234 · Cited by 72
Mitani, T., Yamaji, R., Higashimura, Y., Harada, N., Nakano, Y., & Inui, H. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.10.009 · Cited by 71
Coactivator selective regulation of androgen receptor activity
Agoulnik, I. U., & Weigel, N. L. (2009) · Steroids · doi:10.1016/j.steroids.2009.02.007 · Cited by 69
“The relatively short time of response to androgen deprivation therapy prior to recurrence (typically <2 years) and the evidence that AR is reactivated in recurrent tumors [2] have led to efforts to better understand the factors that regulate AR action in order to develop more effective anti-AR therapies.”
BackgroundEBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance
Zhang, Y., Linn, D. E., Liu, Z., Melamed, J., Tavora, F. R. F., Young, C. Y. F., Burger, A. M., & Hamburger, A. W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0526 · Cited by 68
“Increases in AR protein levels are associated with hormone-refractory disease clinically (2, 3) and in xenograft models of prostate cancer (4).”
BackgroundSerum/glucocorticoid-induced protein kinase-1 facilitates androgen receptor-dependent cell survival
Shanmugam, I., Cheng, G., Terranova, P. F., Thrasher, J. B., Thomas, C. P., & Li, B. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402227 · Cited by 70
Fernandez, E. V., Reece, K. M., Ley, A. M., Troutman, S. M., Sissung, T. M., Price, D. K., Chau, C. H., & Figg, W. D. (2015) · Molecular Pharmacology · doi:10.1124/mol.114.097477 · Cited by 70
Colombel, M. C., Filleur, S., Fournier, P. G. J., Arnold, C., Guglielmi, J., Courtin, A., Degeorges, A., Serre, C. M., Bouvier, R., Clézardin, P., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.300.65.1 · Cited by 63
Loss of testosterone impairs anti-tumor neutrophil function
Markman, J. L., Porritt, R. A., Wakita, D., Lane, M. E., Martinon, D., Rivas, M. N., Luu, M., Posadas, E. M., Crother, T. R., & Arditi, M. (2020) · Nature Communications · doi:10.1038/s41467-020-15397-4 · Cited by 68
Dai, Y., Ngo, D., Jacob, J., Forman, L. W., & Faller, D. V. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn117 · Cited by 65
“Prostate cancer is the second leading cause of cancer death in men ( 1 ,2).”
BackgroundRickman, D. S., Chen, Y.-B., Banerjee, S., Pan, Y., Yu, J., Vuong, T., Perner, S., Lafargue, C. J., Mertz, K. D., Setlur, S. R., et al. (2010) · Neoplasia · doi:10.1593/neo.10866 · Cited by 62
Gauthier-Landry, L., Bélanger, A., & Barbier, O. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.05.009 · Cited by 62
Androgen regulation of the androgen receptor coregulators
Urbanucci, A., Waltering, K. K., Suikki, H. E., Helenius, M. A., & Visakorpi, T. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-219 · Cited by 69
“It has been experimentally shown that overexpression on AR is required and it is sufficient to transform the growth of prostate cancer cells from androgen-dependence to -independence [10].”
BackgroundMinireview: SLCO and ABC Transporters: A Role for Steroid Transport in Prostate Cancer Progression
Cho, E., Montgomery, R. B., & Mostaghel, E. A. (2014) · Endocrinology · doi:10.1210/en.2014-1337 · Cited by 60
AR-V7 and prostate cancer: The watershed for treatment selection?
Ciccarese, C., Santoni, M., Brunelli, M., Buti, S., Modena, A., Nabissi, M., Artibani, W., Martignoni, G., Montironi, R., Tortora, G., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.12.003 · Cited by 68
A novel class of pyranocoumarin anti–androgen receptor signaling compounds
Guo, J., Jiang, C., Wang, Z., Lee, H., Hu, H., Malewicz, B., Lee, H., Lee, J., Baek, N., Jeong, J.-H., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0231 · Cited by 63
“A recent study (8) has shown that an overexpression of the wild-type AR can be a molecular determinant of hormone refractoriness and may turn the best-characterized and clinically used AR antagonist bicalutamide/Casodex (9) into an agonist.”
BackgroundMolecular Pathways: Targeting Resistance in the Androgen Receptor for Therapeutic Benefit
Mostaghel, E. A., Plymate, S. R., & Montgomery, B. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3601 · Cited by 69
A New Trick of an Old Molecule: Androgen Receptor Splice Variants Taking the Stage?!
Guo, Z., & Qiu, Y. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.815 · Cited by 72
“Mounting evidence from both clinical and basic research has demonstrated that AR activity is still required for castration-resistant prostate cancer [4-7].”
BackgroundInhibition of Androgen Receptor Transcriptional Activity as a Novel Mechanism of Action of Arsenic
Rosenblatt, A. E., & Burnstein, K. L. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0235 · Cited by 68
Shiota, M., Song, Y., Takeuchi, A., Yokomizo, A., Kashiwagi, E., Kuroiwa, K., Tatsugami, K., Uchiumi, T., Oda, Y., & Naito, S. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.09.147 · Cited by 66
Requirement for NF-κB in interleukin-4-induced androgen receptor activation in prostate cancer cells
Lee, S. O., Lou, W., Nadiminty, N., Lin, X., & Gao, A. C. (2005) · The Prostate · doi:10.1002/pros.20218 · Cited by 65
“Recent studies suggested that AR activation plays a central role for hormone refractory progression of prostate cancer [41,42].”
TRIM68 Regulates Ligand-Dependent Transcription of Androgen Receptor in Prostate Cancer Cells
Miyajima, N., Maruyama, S., Bohgaki, M., Kano, S., Shigemura, M., Shinohara, N., Nonomura, K., & Hatakeyama, S. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6059 · Cited by 69
“Elucidation of the mechanism of AR activation is essential for understanding process of the prostate cancer progression and for identifying possible targets for intervention (4).”
BackgroundAnuka, E., Gal, M., Stocco, D. M., & Orly, J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.02.003 · Cited by 60
Advances in Androgen Receptor Targeted Therapy for Prostate Cancer
Ahmed, A., Ali, S. S., & Sarkar, F. H. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24456 · Cited by 65
“The AR signaling axis clearly plays a key role in the metastatic progression of PCa, thus identifying various methods by which this signaling pathway could be inhibited will increase the likelihood of better patient prognosis (Chen et al., 2004; Dayyani et al., 2011).”
BackgroundAttardi, B., Burgenson, J., Hild, S. A., & Reel, J. R. (2004) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2004.04.013 · Cited by 60
Androgen receptor levels are upregulated by Akt in prostate cancer
Ha, S., Ruoff, R., Kahoud, N., Franke, T. F., & Logan, S. K. (2011) · Endocrine Related Cancer · doi:10.1530/erc-10-0204 · Cited by 65
“…mechanism of AR gene and protein regulation is underscored by the finding that prostate cancer is reliant on the expression of AR even after progressing to anti-androgen-resistant disease and increased expression of the AR is the major factor driving prostate cancer recurrence (Chen et al. 2004).”
Pu, H., Collazo, J., Jones, E., Gayheart, D. T., Sakamoto, S., Vogt, A. P., Mitchell, B. L., & Kyprianou, N. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0758 · Cited by 73
“Another in vivo study engaging the expression of a DNTGFhRII in mouse skeletal tissue reported that disruption of TGF-h signaling led to prostate cancer metastasis, challenging the existing knowledge that TGF-h is strong promoter of cancer metastasis (12).”
BackgroundMoving Beyond the Androgen Receptor (AR): Targeting AR-Interacting Proteins to Treat Prostate Cancer
Foley, C., & Mitsiades, N. (2016) · Hormones and Cancer · doi:10.1007/s12672-015-0239-9 · Cited by 65
“Alternatively and in addition to point mutations, overexpression of AR (frequently via gene amplification) can also result in firstgeneration AR antagonist-to-agonist conversion [40].”
Lubov, J., Maschietto, M. C., Ibrahim, I., Mlynarek, A., Hier, M., Kowalski, L. P., Alaoui‐Jamali, M. A., & da Silva, S. D. (2017) · Oncotarget · doi:10.18632/oncotarget.19224 · Cited by 61
“Due to its role in cancer progression, several drugs have been proposed to target AR as an alternative treatment [71].”
BackgroundTsai, Y.-C., Chen, W., Abou-Kheir, W. G., Zeng, T., Yin, J. J., Bahmad, H. F., Lee, Y., & Liu, Y. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.02.016 · Cited by 60
Cao, Q., Song, Z., Ruan, H., Wang, C., Yang, X. W., Bao, L., Wang, K., Cheng, G., Xu, T., Xiao, W., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0396 · Cited by 61
“Androgen deprivation therapy (ADT) is the main method for the treatment of advanced prostate cancer.”
BackgroundInfluentialRe, M. D., Conteduca, V., Crucitta, S., Gurioli, G., Casadei, C., Restante, G., Schepisi, G., Lolli, C., Cucchiara, F., Danesi, R., et al. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-020-00309-w · Cited by 63
Tumour markers in prostate cancer II: Diagnostic and prognostic cellular biomarkers
Bjartell, A. S., Montironi, R., Berney, D. M., & Egevad, L. (2011) · Acta Oncologica · doi:10.3109/0284186x.2010.531284 · Cited by 61
“HER2 has also been linked to the clinical progression of CRPC.”
BackgroundLuthold, C., Hallal, T., Labbé, D. P., & Bordeleau, F. (2022) · Cancers · doi:10.3390/cancers14122887 · Cited by 66
Constitutive Activity of the Androgen Receptor
Chan, S. C., & Dehm, S. M. (2014) · Advances in pharmacology · doi:10.1016/b978-0-12-417197-8.00011-0 · Cited by 71
“Indeed, increased AR mRNA and protein levels were observed in prostate cancer xenografts as they progressed to CRPC, and a 2-fold increase in AR expression in LNCaP cells was sufficient for androgen hypersensitization and induction of a CRPC growth phenotype (Chen et al., 2004).”
BackgroundIntegrative Analysis of FOXP1 Function Reveals a Tumor-Suppressive Effect in Prostate Cancer
Takayama, K., Suzuki, T., Tsutsumi, S., Fujimura, T., Takahashi, S., Homma, Y., Urano, T., Aburatani, H., & Inoue, S. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1171 · Cited by 62
Deep, G., Oberlies, N. H., Kroll, D. J., & Agarwal, R. (2008) · Oncogene · doi:10.1038/onc.2008.45 · Cited by 62
“Notably, AR not only mediates the effect of androgen on tumor initiation but also plays major role in the relapse transition (Grossmann et al., 2001; Lee and Chang, 2003a; Chen et al., 2004).”
BackgroundInfluentialMechanisms of prostate cancer cell survival after inhibition of AR expression
Cohen, M. B., & Rokhlin, O. W. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22022 · Cited by 66
“Recent reports have shown that the AR is the key determinant of the molecular changes required for driving prostate cancer cells from an androgen-dependent to an androgen-independent or ADI state [Chen et al., 2004; Isaacs and Isaacs, 2004; Roy-Burman et al., 2005].”
Phenethyl isothiocyanate inhibits STAT3 activation in prostate cancer cells
Gong, A., He, M., Vanaja, D. K., Yin, P., Karnes, R. J., & Young, C. Y. F. (2009) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.200800253 · Cited by 60
“As one of the most prevalent types of malignancy in the United States and many other countries, prostate carcinogenesis has been viewed as a multistage and complex process consisting of initiation, promotion, and progression [24].”
Involvement of Interleukin-6 and Androgen Receptor Signaling in Pancreatic Cancer
Okitsu, K., Kanda, T., Imazeki, F., Yonemitsu, Y., Ray, R. B., Chang, C., & Yokosuka, O. (2010) · Genes & Cancer · doi:10.1177/1947601910383417 · Cited by 65
Lam, H., Nguyen, H. M., Labrecque, M. P., Brown, L. G., Coleman, I. M., Gulati, R., Lakely, B., Sondheim, D., Chatterjee, P., Marck, B. T., et al. (2019) · European Urology · doi:10.1016/j.eururo.2019.05.042 · Cited by 64
“As CRPC develops, AR and AR variants (eg, ARv7) are often adaptively upregulated [1,2], and androgen signaling remains active even upon resistance to ARIs [2–4].”
Saber, S. H., Ali, H. E. A., Gaballa, R., Gaballah, M. S. A., Ali, H. I., Zerfaoui, M., & Elmageed, Z. Y. A. (2020) · Cells · doi:10.3390/cells9030564 · Cited by 64
Zhoul, J., Hernandez, G., Tu, S.-W., Huang, C.-L., Tseng, C.-P., & Hsieh, J.-T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1481 · Cited by 60
“A recent study (3) indicates that overexpression of androgen receptor can cause antagonists to exhibit agonistic activity and also hypersensitizes androgen receptor activity in androgen-independent prostate cancer, which provides these cells”
BackgroundThe methyl-CpG-binding protein MECP2 is required for prostate cancer cell growth
Bernard, D., Gil, J., Dumont, P., Rizzo, S., Monté, D., Quatannens, B., Hudson, D. L., Visakorpi, T., Fuks, F., & de Launoit, Y. (2005) · Oncogene · doi:10.1038/sj.onc.1209179 · Cited by 61
“The main mechanism proposed relies on the AR acquiring the ability to sustain its activity independently of ligand binding or of the presence of AR antagonists (Feldman and Feldman, 2001; Chen et al., 2004; Taplin and Balk, 2004).”
BackgroundPapaioannou, M., Schleich, S., Prade, I., Degen, S., Roell, D., Schubert, U., Tanner, T., Claessens, F., Matusch, R., & Baniahmad, A. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00426.x · Cited by 61
Endocrine disrupting compounds and prostate cancer
Hess-Wilson, J. K., & Knudsen, K. E. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.10.006 · Cited by 73
MAPK4 promotes prostate cancer by concerted activation of androgen receptor and AKT
Shen, T., Wang, W., Zhou, W., Coleman, I. M., Cai, Q., Dong, B., Ittmann, M., Creighton, C. J., Bian, Y., Meng, Y., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135465 · Cited by 61
A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
Crowley, F., Sterpi, M., Buckley, C. W., Margetich, L., Handa, S., & Dovey, Z. (2021) · Research and Reports in Urology · doi:10.2147/rru.s264722 · Cited by 73
Zarif, J. C., Lamb, L. E., Schulz, V. V., Nollet, E. A., & Miranti, C. K. (2015) · Oncotarget · doi:10.18632/oncotarget.3119 · Cited by 69
“The advantage of the PC3-AR model is that we were able to express a mutant of AR that is defective in nuclear localization, and thus lacks transcriptional activity, or is defective in ligand binding [29, 31, 32].”
BackgroundAndrogen Receptor-Target Genes in African American Prostate Cancer Disparities
Wang, B., Yang, Q., Ceniccola, K., Bianco, F. J., Andrawis, R., Jarrett, T. W., Frazier, H. A., Patierno, S. R., & Lee, N. H. (2013) · Prostate Cancer · doi:10.1155/2013/763569 · Cited by 62
“Previous studies have also shown that the cellular AR levels are correlated to primary and metastatic lesions and associated with disease progression to castration-resistant PCa (CRPCa) [8–10].”
BackgroundThe AR dependent cell cycle: Mechanisms and cancer relevance
Schiewer, M. J., Augello, M. A., & Knudsen, K. E. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.06.033 · Cited by 64
“Significantly, it has been shown in multiple model systems that up-regulation of AR alone is sufficient to drive the transition to CRPC, and high nuclear AR levels are predictive for increased risk of death from prostate cancer (Chen et al., 2004; Donovan et al., 2010).”
BackgroundChuang, T., Chen, S.-J., Lin, F., Veeramani, S., Kumar, S., Batra, S. K., Tu, Y., & Lin, M. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.098301 · Cited by 64
Li, X., Liu, Z., Xu, X., Blair, C. A., Sun, Z., Xie, J., Lilly, M. B., & Zi, X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031213 · Cited by 61
Metadata
- Authors
- Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L.
- Affiliations
- University of California, Los Angeles (US)
- Howard Hughes Medical Institute (US)
- University of Washington (US)
- Corresponding author
- Sawyers, Charles L
- Venue
- Nature Medicine
- Published
- 2003-12-21
- Volume
- 10
- Issue
- 1
- Pages
- 33-39
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2003955264
- Cited by
- 2,278
- References
- 50
- Citations by year
- 2026: 21 · 2025: 40 · 2024: 40 · 2023: 72 · 2022: 59 · 2021: 86 · 2020: 68 · 2019: 82 · 2018: 99 · 2017: 110 · 2016: 106 · 2015: 119 · 2014: 128 · 2013: 156 · 2012: 155
- FWCI
- 69.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Keywords
- prostate cancer, antiandrogen resistance, androgen receptor, castration-resistant prostate cancer, androgen receptor ligand-binding domain, coactivator recruitment, corepressor recruitment, androgen receptor target genes
- MeSH terms
- Androgen Antagonists, Base Sequence, Humans, Male, Prostatic Neoplasms, Receptors, Androgen, DNA Primers, Disease Progression, Antineoplastic Agents, Hormonal, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.